Stock BMEA BIOMEA FUSION, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
4.14 USD -63.27% Intraday chart for Biomea Fusion, Inc. -60.65% -71.49%
Jun. 07 Sector Update: Health Care Stocks Higher Late Afternoon MT
Jun. 07 Top Midday Decliners MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
PR
Sector Update: Health Care Stocks Higher Late Afternoon
MT
Top Midday Decliners
MT
Piper Sandler Adjusts Price Target on Biomea Fusion to $10 From $45, Maintains Overweight Rating
MT
Scotiabank Cuts Price Target on Biomea Fusion to $21 From $41, Maintains Sector Outperform Rating
MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
MT
Jobs Growth Tops Forecasts as US Equity Futures Post Narrow Losses Pre-Bell
MT
Top Premarket Decliners
MT
Barclays Downgrades Biomea Fusion to Equalweight From Overweight, Adjusts Price Target to $5 From $30
MT
Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold; Shares Plummet Premarket
MT
Biomea Fusion Down 61% on Clinical Hold for Diabetes Drug
DJ
Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold
MT
U.S. FDA places hold on Biomea's diabetes trial
RE
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
GL
Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold
CI
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GL
Biomea Fusion Completes Enrollment of First 3 Dose Expansion Arms of Diabetes Trial
MT
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
GL
Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
CI
Oppenheimer Adjusts Biomea Fusion Price Target to $60 From $70, Maintains Outperform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMEA Stock
  4. News Biomea Fusion, Inc.